Methylene Blue 50mg

Oral capsule: Swallow intact with a full glass of water. May be taken with food to reduce GI upset. Blue-green discoloration of urine and stool is expected. At 50 mg doses, patients should be counseled about the increased likelihood of transient skin tingling or discoloration and GI effects. Avoid direct sunlight exposure to skin if photosensitivity develops. Do not chew or open the capsule.

Dosing is entirely prescriber-determined based on the specific clinical indication.

• The 50 mg oral dose represents a higher-range compounded formulation; protocols vary by indication and patient weight.
• Prescribers may order once-daily or divided dosing depending on the pharmacokinetic goals of the regimen (terminal half-life approximately 5.25 hours IV; oral pharmacokinetics vary).
• There are no FDA-approved oral dosing guidelines for off-label indications at this strength — dosing is based on the prescriber's clinical judgment and available literature.

• Methylene Blue (50 mg): At higher doses, methylene blue's inhibition of nitric oxide synthase and soluble guanylate cyclase is more complete, reducing cGMP-mediated vascular smooth muscle relaxation — the basis of its use in vasoplegic shock states. The electron-cycling activity in the mitochondrial electron transport chain (bypassing Complexes I–III by shuttling electrons directly to cytochrome c) continues to enhance cellular ATP production and reduce mitochondrial superoxide. The MAO-A inhibitory effect also persists, though serotonin syndrome risk is amplified at higher doses when combined with serotonergic drugs. Note: at very high doses (>7 mg/kg), methylene blue can paradoxically oxidize hemoglobin and cause methemoglobinemia.

The 50 mg oral compounded formulation is used under prescriber direction for off-label clinical applications that may include: continuity of care after IV methylene blue treatment for vasoplegic episodes, ifosfamide encephalopathy prevention or adjunctive management, or as part of investigational neurological support protocols. All uses at this dose are off-label and not FDA-approved for oral compounded administration.

Monitoring considerations:

• G6PD status must be confirmed before use — G6PD-deficient patients cannot safely receive methylene blue
• Complete blood count to monitor for hemolysis
• Pulse oximetry and methemoglobin levels if hemolytic or cyanotic symptoms develop
• Strict serotonergic medication reconciliation — risk of serotonin syndrome is higher at 50 mg than at lower doses
• Hepatic function — methylene blue undergoes hepatic metabolism

Contraindications:

• G6PD deficiency (hemolytic anemia risk)
• Hypersensitivity to methylene blue or phenothiazine dyes
• Concurrent serotonergic drugs (serotonin syndrome risk)
• Concurrent apomorphine (severe hypotension)

Warnings & Precautions:

• Serotonin syndrome: risk escalates at higher doses — avoid with SSRIs, SNRIs, MAOIs, triptans, linezolid, or other serotonergic agents
• Paradoxical methemoglobinemia: high doses (>7 mg/kg) can cause, rather than treat, methemoglobinemia
• Skin and mucous membrane discoloration at higher cumulative doses
• Photosensitivity — avoid prolonged UV/sun exposure

Drug Interactions:

• Serotonergic agents: potentially fatal serotonin syndrome
• Apomorphine: life-threatening hypotension
• CYP2C19 substrates: potential inhibition

Common Side Effects: Blue-green urine/stool, nausea, GI cramping, headache, dizziness, skin tingling, photosensitivity; higher doses may cause restlessness, confusion, or hemolysis in susceptible individuals.

Store in a light-resistant container at controlled room temperature (15–25°C), protected from moisture and heat. Methylene blue is highly photosensitive — prolonged light exposure can degrade the active compound. Observe the beyond-use date assigned by Genesis Compounding. Dispose of unused product per local regulations.

How does the 50 mg dose differ from the 15 mg dose?

The 50 mg dose provides greater systemic exposure and more complete inhibition of nitric oxide synthase and guanylate cyclase, making it suitable for indications requiring more robust nitric oxide pathway modulation. The safety considerations — particularly serotonin syndrome and hemolysis — are proportionally more relevant at this dose.

Will I see more discoloration of urine at this dose?

Yes. Blue-green urine and potentially stool discoloration will be more pronounced at 50 mg than at 15 mg. This is expected, benign, and resolves after discontinuation.

Is this safe to take with my antidepressant?

Methylene blue at any dose can cause severe serotonin syndrome with SSRIs, SNRIs, MAOIs, and related serotonergic drugs. This is a critical safety concern; your prescriber must review all medications before authorizing this preparation.

Is this FDA-approved?

Oral methylene blue is not FDA-approved for any indication. The IV formulation (ProvayBlue) is FDA-approved only for methemoglobinemia. This 50 mg oral preparation is a prescriber-directed, patient-specific 503A compounded product for off-label clinical use.

How should I store this capsule?

In a light-resistant container at room temperature, away from moisture and heat. Observe the beyond-use date and do not use after expiration.